To elucidate the mode of action of Epstein-Barr virus (EBV), we have examined the possibility that EBV infection may lead to a change in oncogene expression. Levels of oncogene-related RNA were compared in the Burkitt lymphoma (BL)-derived, EBV-negative cell line BJAB and in two isogenic, EBV-converted sublines of BJAB whose growth characteristics differ from the EBV-negative parent line. The oncogenes c-myc, Ha-ras, and Blym were each found to be expressed at equally high levels in the three cell lines. This suggests that the mechanism of action of EBV in altering the growth properties of lymphoid cells is not dependent on the induction of cellular oncogenes. In addition, since the 8,14 chromosomal translocation has been related to increased c-myc expression in BL cells, a karyotype analysis was done to confirm the initial report of a normal karyotype in BJAB cells. Chromosomes 8 and 14 were seen to be normal. Thus, BJAB cells are a BL cell line in which the elevated expression of c-myc is independent not only of EBV but also of translocations involving chromosome 8.

Keywords:
Oncogenes, c-myc, Epstein-Barr virus, Burkitt lymphoma, 8,14 translocation
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.